ストックスクリーナーアプリを入手
53.24
0.76%
-0.41
プレマーケット:
53.24
前日終値:
$53.65
開ける：
$53.48
24時間の取引高:
377.75K
Relative Volume:
0.53
時価総額：
$4.10B
収益：
$754.05M
当期純損益:
$73.06M
株価収益率:
58.68
EPS:
0.9073
ネットキャッシュフロー:
$164.23M
1週間 パフォーマンス:
-5.79%
1か月 パフォーマンス:
+23.70%
6か月 パフォーマンス:
+28.04%
1年 パフォーマンス:
+105.16%
1日の値動き範囲:
$53.02
$55.08
1週間の範囲:
$52.31
$57.01
52週間の値動き範囲:
$25.70
$59.87
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
名前
Kiniksa Pharmaceuticals International Plc
セクター
電話
(781) 431-9100
住所
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
53.24 | 4.13B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-09-29 | 開始されました | TD Cowen | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2024-05-03 | 開始されました | Wells Fargo | Overweight |
| 2020-06-29 | 繰り返されました | BofA Securities | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-12-12 | 繰り返されました | Wedbush | Outperform |
| 2018-06-19 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Kiniksa Pharmaceuticals International Plc (KNSA) 最新ニュース
UBS Group AG Purchases 28,099 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (KNSA) price target increased by 10.10% to 63.53 - MSN
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Vanguard Group Inc. Acquires 49,802 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month HighStill a Buy? - MarketBeat
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Kiniksa Pharmaceuticals International : 2025 Annual Report - marketscreener.com
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Why Kiniksa Pharmaceuticals International stock raced nearly 24% higher today - MSN
FMR LLC amends filing showing 6,787,700.23 Kiniksa holdings (KNSA) - Stock Titan
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares - MarketBeat
Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026) - Minichart
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance - Yahoo Finance
Sanj Patel Sells 48,565 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor - TipRanks
Kiniksa Pharmaceuticals (KNSA) insider sale notice lists 58,424 shares - Stock Titan
Kiniksa (NASDAQ: KNSA) CSO Tessari resigns, signs $450/hour consulting deal - Stock Titan
Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan - Stock Titan
KNSA SEC FilingsKiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms - Stock Titan
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results - Insider Monkey
Kiniksa Pharmaceuticals International, plc Announces Executive Changes - marketscreener.com
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,217,601.44 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in Stock - MarketBeat
Sanj Patel Sells 483,654 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa (NASDAQ: KNSA) CEO’s plan-based option exercises and 508K share sales detailed - Stock Titan
Pictet Asset Management Holding SA Has $32.49 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA Maintained by Citigroup -- Price Target Raised to $60 - GuruFocus
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $656,260, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 13,099 Shares of Stock - MarketBeat
Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan - Stock Titan
KNSA Maintained by Wedbush -- Price Target Raised to $59.00 - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) tops Q1 earnings and revenue estimates - MSN
KNSA Maintained by Wells Fargo -- Price Target Raised to $57 - GuruFocus
Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - MarketBeat
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation (KNSA) - Seeking Alpha
9 Best Drug Stocks to Buy According to Analysts - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earning - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High Following Strong Earnings - MarketBeat
Kiniksa Pharmaceuticals International Plc (KNSA) 財務データ
収益
当期純利益
現金流量
EPS
1.92%
4.44%
大文字化:
|
ボリューム (24 時間):